News releases from Eli Lilly and Company
Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event
June 12, 2020
The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor...
Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020. Joshua Smiley, senior vice president and Lilly's chief...
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
June 08, 2020
- The first healthy volunteer has been dosed in a Phase 1 study of JS016, the lead antibody from Lilly's collaboration with Junshi Biosciences
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
June 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
June 03, 2020
-- Long-term results from SPIRIT-H2H show robust efficacy of Taltz as monotherapy or in combination with methotrexate or additional csDMARDs --
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
June 01, 2020
- Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA -
- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
May 29, 2020
CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the...
Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease
May 28, 2020
President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D Senior Savings Model that will allow people in the...
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction
May 26, 2020
- Ischemic heart disease, including myocardial infarction, is the leading cause of death in the U.S.
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
May 26, 2020
Emgality® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month...
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease
May 19, 2020
Latest Phase 1/2 LIBRETTO-001 registrational trial data examining Retevmo™ (selpercatinib) demonstrate commitment to advancing precision medicines for hard-to-treat tumor types
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
May 08, 2020
- Approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes
May 08, 2020
New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight reductions up to 10.4 pounds in people...
Eli Lilly and Company (NYSE: LLY) will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020. Michael Mason, Lilly senior vice president and president of Lilly Diabetes...
Lilly Declares Second-Quarter 2020 Dividend
May 04, 2020
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding common stock.
Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
May 04, 2020
Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment...
Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2020 Health Care Conference on Wednesday, May 13, 2020. Patrik Jonsson, Lilly senior vice president and president of...
- Revenue in the first quarter of 2020 increased 15 percent, driven by 22 percent volume growth. Strong underlying demand for key growth products was augmented by approximately $250 million of...
Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available
April 16, 2020
Lilly Begins Clinical Testing of Therapies for COVID-19
April 10, 2020
Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement
April 08, 2020
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020. Lilly will also conduct a conference call on that day with the investment community...
Eli Lilly and Company (NYSE: LLY) announced today that due to the public health impact of the coronavirus outbreak, and to support the health and well-being of its employees, shareholders, and other...
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
April 07, 2020
Insulin savings available for people with commercial insurance and the uninsured by calling (833) 808-1234
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
March 31, 2020
Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
March 30, 2020
Updates from Lilly about insulin supply and affordability
March 24, 2020
To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: